Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia

On June 3, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

CenterPoint Energy Announces Completion of VUHI Restructuring to Enable More Efficient Funding of Capital Investments for the Benefit of Customers

Dover Completes Acquisition of Malema Engineering Corporation

KLA Announces Fourth Quarter Fiscal Year 2022 Earnings Date